- Original article
- Open Access
Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells
© The Author(s) 2017
- Received: 8 March 2017
- Accepted: 16 May 2017
- Published: 31 July 2017
The mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor trametinib has shown promising therapeutic effects on melanoma, but its efficacy on colorectal cancer (CRC) is limited. Synthetic lethality arises with a combination of two or more separate gene mutations that causes cell death, whereas individual mutations keep cells alive. This study aimed to identify the genes responsible for resistance to trametinib in CRC cells, using a synthetic lethal short hairpin RNA (shRNA) screening approach.
We infected HT29 cells with a pooled lentiviral shRNA library and applied next-generation sequencing to identify shRNAs with reduced abundance after 8-day treatment of 20 nmol/L trametinib. HCT116 and HT29 cells were used in validation studies. Stable ring finger protein 183 (RNF183)-overexpressing cell lines were generated by pcDNA4-myc/his-RNF183 transfection. Stable RNF183-knockdown cell lines were generated by infection of lentiviruses that express RNF183 shRNA, and small interference RNA (siRNA) was used to knock down RNF183 transiently. Quantitative real-time PCR was used to determine the mRNA expression. Western blotting, immunohistochemical analysis, and enzyme-linked immunosorbent assay (ELISA) were used to evaluate the protein abundance. MTT assay, colony formation assay, and subcutaneous xenograft tumor growth model were used to evaluate cell proliferation.
In the primary screening, we found that the abundance of RNF183 shRNA was markedly reduced after treatment with trametinib. Trametinib induced the expression of RNF183, which conferred resistance to drug-induced cell growth repression and apoptotic and non-apoptotic cell deaths. Moreover, interleukin-8 (IL-8) was a downstream gene of RNF183 and was required for the function of RNF183 in facilitating cell growth. Additionally, elevated RNF183 expression partly reduced the inhibitory effect of trametinib on IL-8 expression. Finally, xenograft tumor model showed the synergism of RNF183 knockdown and trametinib in repressing the growth of CRC cells in vivo.
The RNF183-IL-8 axis is responsible for the resistance of CRC cells to the MEK1/2 inhibitor trametinib and may serve as a candidate target for combined therapy for CRC.
- Synthetic lethal
- Colorectal cancer
- Ring finger protein 183
- Mitogen-activated extracellular signal-regulated kinase 1/2
Colorectal cancer (CRC) is the third most common malignancy worldwide . The mechanisms underlying the initiation and development of CRC are complex and involve many key pathways, such as the Wnt, mitogen-activated protein kinase (MAPK), and transforming growth factor-β (TGF-β) signaling pathways [2–5]. Mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) is a dual threonine- and tyrosine-recognizing kinase that phosphorylates and activates kinases in the MAPK signaling pathway . Although MEK inhibitors are currently used in targeted therapy for melanoma, MEK inhibitor monotherapy (such as trametinib) was found to be ineffective for CRC . Many mechanisms of resistance to trametinib have been identified, including activation of upstream receptor tyrosine kinases and stimulation of parallel signals bypassing MEK inhibition to reactivate extracellular signal-regulated kinase (ERK) signaling . Therefore, rational drug combinations, potentially with agents targeting proteins that confer resistance to MEK inhibitors, are likely to improve the therapeutic efficacy.
Synthetic lethality was originally identified in gene function studies in drosophila, which means that a combination of two or more separate gene mutations causes cell death, whereas individual mutations keep cells alive . This strategy could be used to identify therapeutic targets against cancer. For example, ovarian cancer cells with mutations of the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) have good response to poly(ADP-ribose) polymerase (PARP) inhibitors . The use of genome-wide approaches, such as short hairpin RNA (shRNA) and clustered regularly interspaced short palindromic repeats (CRISPR)-based screening libraries, plus next-generation sequencing largely facilitate the process of identifying genes that confer synthetic lethality with drugs. An increasing number of targets have been identified, and new combination strategies were developed and validated in preclinical studies [9, 10].
The RING finger (RNF) protein family is a complex set of proteins containing a RING finger domain with 40–60 amino acids [11, 12]. Although it has been reported that many RNF members play key roles in carcinogenesis [13–15], their association with CRC is largely unknown. The expression of RNF183 was found to be up-regulated in inflammatory bowel disease (a causative factor for CRC) and to activate the classical nuclear factor-kappaB (NF-κB) pathway [16–18]. It has not, however, been reported whether RNF183 plays a role in CRC. In this study, we used a synthetic lethal shRNA screening to identify genes conferring resistance to trametinib in CRC cell line HT29. Furthermore, we investigated whether RNF183 could serve as a possible target for combined therapy for CRC.
Cell lines and cell culture
Colorectal cancer cell lines HCT116 and HT29 were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in McCoy’s 5A medium (Gibco, Grand Island, NY, USA) supplied with 10% fetal bovine serum (Hyclone, Irvine, CA, USA) in a humidified atmosphere of 5% CO2 at 37 °C. Thawed cells from liquid nitrogen were used within the first three passages.
Plasmids, antibodies, and reagents
Sequences of human ring finger protein 183 (RNF183) and interleukin-8 (IL-8) that were targeted by small interfering RNAs (siRNAs) and short hairpin RNA (shRNA)
The antibodies used are as follows: anti-human RNF183 antibody (dilution of 1:1000 for Western blotting, 1:200 for immunohistochemical analysis [IHC], ab197321; Abcam, Cambridge, UK), anti-β-actin antibody (dilution of 1:200 for Western blotting, sc-47778; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-mouse IgG HRP conjugate (dilution of 1:8000 for Western blotting, W402B; Promega, Madison, WI, USA), anti-rabbit IgG HRP conjugate (dilution of 1:2000 for Western blotting, #7074P2; Cell Signaling Technology, Wellesley, MA, USA), and anti-Ki-67 antibody (dilution of 1:200 for IHC, #12202; Cell Signaling Technology).
The protein level of IL-8 in culture supernatant was determined using a human IL-8 enzyme-linked immunosorbent assay (ELISA) kit (Proteintech, Wuhan, Hubei, China). Trametinib was obtained from Selleck Chemicals (Houston, TX, USA) and dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) at 50 mmol/L and stored at −80 °C for in vitro experiments. It was reconstituted in distilled H2O containing 0.5% hydroxypropyl methylcellulose (Sigma-Aldrich) and 0.2% Tween-80 (Sigma-Aldrich) for in vivo experiments. The reagent 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was also obtained from Sigma-Aldrich.
shRNA screening and bioinformatics analysis
A lentiviral shRNA library (catalog number: SHPH01) consisting of over 150,000 shRNA constructs targeting more than 15,000 human genes was obtained from Sigma-Aldrich. HT29 cells were transfected with the lentiviral shRNA library at a multiplicity of infection of 0.4, and stable cell lines were generated by puromycin selection for 7 days. Then, these stable cells were divided into two groups and treated with DMSO or 20 nmol/L trametinib for an additional 8 days. The genomic DNA of treated stable cells was extracted, and the shRNA fragment was amplified using primers flank the insertion site of the lentiviral vector, which were provided by the library manufacturer. The amplicon was subjected to next-generation sequencing using a Hiseq 4000 sequencer (Illumina, San Diego, CA, USA), and the abundance of each shRNA in each treatment group was calculated. Genes were considered responsible for trametinib resistance when the following three conditions were met: (1) the abundance of the shRNA for this gene in the DMSO group was higher than 25 per million sequences; (2) the abundance of the shRNA for this gene in the trametinib group was lower than that in the DMSO group; and (3) the P value for the difference in the shRNA abundance between the DMSO and trametinib groups was smaller than 0.01.
RNA extraction and quantitative real-time PCR
Primer sequences for quantitative real-time PCR
Product length (bp)
After 48-h treatment with trametinib, HT29 and HCT116 cells were lysed with cell lysis buffer containing phosphatase inhibitor and protease inhibitor (Sigma-Aldrich). The supernatants were collected and measured using a BCA protein assay kit (KeyGEN BioTECH, Nanjing, Jiangsu, China). For each sample, 35 μg of protein lysis was used for immunoblotting. Proteins were separated by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane. The protein band was visualized using electrochemiluminescence (KeyGEN BioTECH).
Establishment of stable cell lines
HT29 and HCT116 cells were transfected with pcDNA4-myc/his-RNF183 or pcDNA4-myc/his using Lipofectamine2000 (Invitrogen). After 48-h transfection, the cells were treated with 300 μg/mL zeocin (Invitrogen) for an additional 12 days to select cells stably expressing RNF183 and control cells. The shRNF183 and shNC lentiviral vectors were generated by GenePharma and transfected into HCT116 and HT29 cells. Stable cell lines with RNF183 knockdown and control cells were selected in the presence of 3 μg/mL puromycin for 7 days, respectively.
Cell viability, apoptosis, and cytotoxicity assays
Cell viability was measured with MTT assay. Briefly, cells were planted in a 96-well plate (3000 cells per well) and incubated for 1, 2, and 3 days with or without trametinib (20 nmol/L). The medium was then replaced with 5 mg/mL MTT solution, followed by incubation for another 4 h. Subsequently, MTT solution was removed, and DMSO was added to dissolve crystals. Finally, the absorbance was measured at 490 nm (A 490). Each measurement was performed in triplicate. The proliferation rate was calculated: relative proliferation rate = A 490 of the siIL-8 group/A 490 of the siNC group × 100%.
Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis assay kit was purchased from BestBio (Nanjing, Jiangsu, China), and lactate dehydrogenase (LDH) secretion kit was purchased from Promega. Cells were seeded in 6-well plates at the density of 3 × 105 cells per well and treated with trametinib for 72 h. The supernatant was collected for cytotoxicity evaluation, i.e., LDH detection. Briefly, 50 μL supernatant and 50 μL CytoTox 96® reagent (Promega) were added into each well of a 96-well plate. After 30-min incubation at room temperature, 50 μL of stop solution was added to each well. Finally, the absorbance, A 490, was measured. The LDH release rate was calculated using the following formula: LDH release rate = A 490 of the experimental LDH release group/A 490 of the reference maximum LDH release group × 100%.
The adherent cells were prepared for apoptosis assay. Briefly, cells were trypsinized and washed twice with 1× phosphate buffer saline (PBS) and re-suspended in binding buffer. Next, 5 μL annexin V-FITC and 10 μL PI were transferred into cell suspensions. After incubation for 15 min at 4 °C, apoptotic cells were detected on FACSCalibur (BD, Heidelberg, Germany).
Colony formation assay
For colony formation assay, stable RNF183-overexpressing and control cells transfected with pcDNA4-myc/his were planted in 6-well flat-bottom plates (3 × 105 cells per well). When the cells were 50%–60% confluent, siRNA targeting IL-8 or control siRNA (Ribobio) were transiently transfected into cells using Lipofectamine2000. After 48 h, cells were digested with trypsin (Gibco) and planted into new 6-well plates at a density of 500 cells per well. After being cultured in an incubator for 10 days, the medium was discarded, and cells were washed twice with 1× PBS. Then, the colonies were stained with 5% crystal violet for 15 min, and visible colonies containing at least 50 cells were counted.
Xenograft tumor growth model
All animal experiments strictly complied with institutional ethical and safety guidelines (Institutional Animal Welfare and Ethics Committee, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China). 5- to 6-week-old female BALB/c nude mice were purchased from SLAC Laboratory Animal Inc. (Shanghai, China). We selected HCT116 cells for in vivo experiments. Twenty-four mice were equally distributed into two groups. They were inoculated by subcutaneous injection of 1 × 106 stable shRNF183- or shNC-expressing HCT116 cells. After 7 days, when the median tumor volume exceeded 100 mm3, each group was again divided into a trametinib treatment subgroup and a vehicle injection subgroup (each subgroup contained 6 mice), with daily oral administration of 300 μg/kg trametinib or vehicle (distilled H2O containing 0.5% hydroxypropyl methylcellulose and 0.2% Tween-80) for 23 days. Tumor length and width were measured every 4 days until the completion of trametinib treatment. The volume (V) was calculated using the conventional formula: V = (L × W 2)/2, where “L” and “W” are the length and width of the tumor. Finally, the mice were euthanized, and tumors were resected and photographed. Tumor size and weights were measured. Total RNA was extracted from tumors for IL-8 detection as described above. The remaining tumor specimens were fixed in 4% formaldehyde and then embedded in paraffin to make slices for Ki-67, RNF183, and hematoxylin–eosin (H&E) staining.
Immunohistochemical (IHC) assay
IHC assay was conducted using the DAB Detection Kit (GeneTech, Shanghai, China). Slides were immersed into 0.01 mol/L citrate buffer (ZSGB-BIO, Beijing, China) and boiled at 98 °C for 15 min in a microwave for antigen retrieval. Endogenous peroxidases were blocked with 3% H2O2 in methanol for 30 min, and non-specific protein binding was blocked with staining blockers (GeneTech). The samples were incubated with anti-RNF183 antibody or anti-Ki-67 antibody at 4 °C overnight. Then, the slides were washed three times with 1× PBS and incubated with the secondary antibody (GeneTech) at room temperature for 1 h. Then, DAB solution was added to slides for staining according to the manufacturer’s protocol. The tissues on slides were fixed and photographed using a microscope camera (Nikon, Tokyo, Japan).
Statistical analyses were performed using SPSS version 16.0 software (SPSS Inc., Chicago, IL, USA). Student’s t test was used for comparisons. P values less than 0.05 were considered statistically significant.
Synthetic lethal shRNA screening identified RNF183 as a trametinib-resistant gene
RNF183 expression was increased after trametinib treatment and conferred drug resistance in CRC cells
Next, we evaluated the effects of RNF183 on apoptotic and non-apoptotic death of CRC cells. RNF183 overexpression significantly decreased the percentages of apoptotic cells in both HT29 and HCT116 cells (all P < 0.05) (Fig. 2e, f, left), whereas RNF183 knockdown promoted apoptosis (all P < 0.05) (Fig. 2e, f, right) with or without trametinib treatment. LDH release is a biomarker for the occurrence of cytotoxicity and cytolysis that could reflect non-apoptotic death. We found that RNF183 overexpression markedly inhibited trametinib-induced LDH release from HCT116 and HT29 cells (all P < 0.05) (Fig. 2g, h, left), whereas RNF183 knockdown increased LDH release in both cell lines with or without trametinib treatment (all P < 0.05) (Fig. 2g, h, right).
IL-8 expression was induced by RNF183 to promote cell growth
Subsequently, we evaluated whether RNF183 affects trametinib-induced IL-8 down-regulation in HCT116 cells. RNF183 overexpression significantly induced IL-8 expression and partly counteracted trametinib-induced repression of IL-8 expression (P < 0.05) (Fig. 3d, left). Transfection of RNF183 siRNA significantly repressed IL-8 expression, and administration of trametinib synthetically decreased the abundance of IL-8 mRNA (P < 0.001) (Fig. 3d, right). Detection of IL-8 protein concentration in the medium showed similar results (P < 0.05) (Fig. 3e).
Because RNF183 expression was induced by trametinib and suppressed trametinib-induced inhibition on cell proliferation, and because IL-8 is a downstream target of RNF183, we evaluated the role of IL-8 in RNF183-enhanced growth of HCT116 cells using colony formation assay. RNF183 overexpression significantly increased the number of colonies, whereas this effect was largely diminished by IL-8 knockdown (P < 0.001) (Fig. 3f). Moreover, knockdown of IL-8 synergistically repressed the proliferation of HT29 and HCT116 cells with trametinib treatment (P < 0.01) (Fig. 3g). These results suggested that IL-8 was a potential mediator of RNF183 in overcoming trametinib-induced growth inhibition of CRC cells.
RNF183 conferred resistance to trametinib in vivo
In the present study, we conducted synthetic lethal shRNA screening and showed that RNF183 conferred resistance to trametinib in CRC cells. Moreover, IL-8 was induced by RNF183, and IL-8 knockdown showed synergistic effects with trametinib on inhibiting proliferation of CRC cells.
It has been reported that BRAF (B-Raf proto-oncogene) and KRAS (KRAS proto-oncogene) mutations in CRC predicted resistance to anti-EGFR (epidermal growth factor receptor) therapy , and CRC cells were less responsive to anti-BRAF and anti-MEK therapies [27–29]. The combination of other targeted therapies significantly improved the effects of trametinib. For example, the combination of trametinib and CDK4/6 (cyclin dependent kinase 4/6) inhibitor was shown to be highly efficacious in inhibiting the growth of KRAS-mutant CRC cells and inducing the tumor regression in patient-derived xenograft models of CRC . CDK6 as well as other genes reported to cause trametinib resistance, such as HDAC  and FGFR , were also identified in our primary screening. In addition, we found some new genes not previously reported to confer trametinib resistance, including RNF183. RNF183 could activate the NF-κB signaling pathway by increasing the ubiquitination and degradation of NF-κB inhibitor α (IκBα), and IL-8 is a downstream target of this proinflammatory signaling pathway . The MAPK signaling pathway has been reported to be involved in regulating IL-8 expression . We found that trametinib treatment significantly decreased IL-8 levels while up-regulating RNF183 expression in both KRAS-mutated (HCT116) and BRAF-mutated (HT29) CRC cells. Moreover, since IL-8 can be targeted by specific agents such as siRNA and antibody, its role in growth and trametinib resistance of CRC cells suggests that it could serve as a therapeutic target. We further found that, compared with trametinib monotherapy, the combination of RNF183 knockdown with trametinib markedly attenuated the proliferation and increased apoptosis and death of CRC cells, suggesting a synergism of these two treatments. In addition, as a member of E3 ubiquitin ligase containing ring finger domain, RNF183 has been shown to be involved in partial resistance to trametinib in CRC cells. It has been reported that the cancer therapy of inhibition ubiquitin ligase was exciting . Therefore, RNF183 can be a new candidate for further research on ubiquitin ligase and may be a potential target gene for CRC therapy.
There are several limitations in the present study. The coverage of the shRNA library used in our study was not large enough. The library targets 15,000 genes, which covers about a half of human genes. Generation of an shRNA library with more reliable targeting sequences and higher genomic coverage could more accurately identify genes that confer drug resistance. Further research using stable RNF183-overexpressing cells to investigate trametinib resistance in vivo is needed. Furthermore, investigating the role of other candidate genes in trametinib resistance is also required.
Taken together, our data suggest that RNF183 and IL-8 are potential synergistic targets for anti-MEK therapy for CRC.
The authors contributed in the following way: conception and design, RG, SC, and WH; development of methodology, WS, SC, and RL; acquisition of data (including providing animals, providing facilities, etc.), RG, XT, WS, ZP, GW and CY; analysis and interpretation of data (e.g. statistical analysis, biostatistics, computational analysis), RG, ZZ, JW, JL, LQ, SC and WH; writing, review, and/or revision of the manuscript, RG and SC; study supervision, SC. All authors read and approved the final manuscript.
This study was supported by the National Natural Science Foundation of China (Nos. 81672744, 81472252), Science and Technology Project of Guangdong Province (No. 2016A020217007), and Guangdong Esophageal Cancer Institute (No. M201606).
The authors declare that they have no competing interests.
The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (http://www.researchdata.org.cn), with the Approval Number as RDDB2017000082.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 2009;10(6):353–8.View ArticlePubMedGoogle Scholar
- Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.View ArticlePubMedGoogle Scholar
- Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14(25):3937–47.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamagishi H, Kuroda H, Imai Y, Hiraishi H. Molecular pathogenesis of sporadic colorectal cancers. Chin J Cancer. 2016;35:4.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 2015;34(9):384–93.PubMedGoogle Scholar
- Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):773–81.View ArticlePubMedGoogle Scholar
- Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, et al. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia. 2013;15(2):143–55.View ArticlePubMedPubMed CentralGoogle Scholar
- Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017;7(1):20–37.View ArticlePubMedGoogle Scholar
- Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47(3):250–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–3.View ArticlePubMedGoogle Scholar
- Nakamura N. The role of the transmembrane RING finger proteins in cellular and organelle function. Membranes (Basel). 2011;1(4):354–93.View ArticlePubMedPubMed CentralGoogle Scholar
- Ho SR, Mahanic CS, Lee YJ, Lin WC. RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage. Proc Natl Acad Sci USA. 2014;111(26):E2646–55.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhu J, Zhao C, Zhuang T, Jonsson P, Sinha I, Williams C, et al. RING finger protein 31 promotes p53 degradation in breast cancer cells. Oncogene. 2016;35(15):1955–64.View ArticlePubMedGoogle Scholar
- Giannakis M, Hodis E, Jasmine MX, Yamauchi M, Rosenbluh J, Cibulskis K, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014;46(12):1264–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2013;110(31):12649–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Yu Q, Zhang S, Chao K, Feng R, Wang H, Li M, et al. E3 ubiquitin ligase RNF183 is a novel regulator in inflammatory bowel disease. J Crohn’s Colitis. 2016;10(6):713–25.View ArticleGoogle Scholar
- Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375–81.View ArticlePubMedGoogle Scholar
- Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145(1):166–75.View ArticlePubMedGoogle Scholar
- Chen S, Sheng C, Liu D, Yao C, Gao S, Song L, et al. Enhancer of zeste homolog 2 is a negative regulator of mitochondria-mediated innate immune responses. J Immunol. 2013;191(5):2614–23.View ArticlePubMedGoogle Scholar
- Song L, Gao S, Jiang W, Chen S, Liu Y, Zhou L, et al. Silencing suppressors: viral weapons for countering host cell defenses. Protein Cell. 2011;2(4):273–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen S, Zhao X, Tan J, Lu H, Qi Z, Huang Q, et al. Structure-based identification of small molecule compounds targeting cell cyclophilin a with anti-HIV-1 activity. Eur J Pharmacol. 2007;565(1–3):54–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, et al. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 2016;7(26):39595–608.View ArticlePubMedPubMed CentralGoogle Scholar
- Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, et al. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017;8(10):16367–86.PubMedPubMed CentralGoogle Scholar
- Manchado E, Weissmueller S, Morris JT, Chen CC, Wullenkord R, Lujambio A, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534(7609):647–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Hartman ML, Rozanski M, Osrodek M, Zalesna I, Czyz M. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells. Lab Invest. 2017;97(2):217–27.View ArticlePubMedGoogle Scholar
- Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13–21.View ArticlePubMedGoogle Scholar
- Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.View ArticlePubMedGoogle Scholar
- Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705–12.View ArticlePubMedGoogle Scholar
- Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Shah SA, Potter MW, Callery MP. Ubiquitin proteasome pathway: implications and advances in cancer therapy. Surg Oncol. 2001;10(1–2):43–52.View ArticlePubMedGoogle Scholar